Biogen Inc. BIIB NASDAQ

Biogen Inc. (BIIB) generated $2.2B in operating cash flow for fiscal year 2025. After capital expenditures of $153.8M, free cash flow was $2.05B.

Free cash flow margin was 20.9% of revenue. Cash conversion ratio was 1.71x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (65/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (55/100) — Cash conversion ratio was 1.71x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 60/100 with 2/7 criteria passed.